Feature | June 26, 2013

New Boston Scientific Pacemaker Family Features Technology for Adapting Pacing to Respiration

Boston Scientific Formio Vitalio Inliven Pacemakers EP Lab

June 26, 2013 — Boston Scientific Corporation is launching a new family of pacemakers in Europe. These pacemakers monitor respiration, adjust pacing accordingly, and support insight into the patient's overall heart failure status. Comprising of the Inliven cardiac resynchronization therapy pacemaker (CRT-P) that synchronizes the heart chambers, and the Vitalio and Formio pacing systems, the new family of devices offers clinicians a comprehensive set of tools for the management of heart failure and related comorbidities.

Pacing systems are designed to treat bradycardia, a condition in which the heart beats too slowly, depriving the body of sufficient oxygen, whereas CRT-P systems are designed to treat heart failure patients.

"The new family of devices is able to offer a unique perspective on the patient's pacing status by monitoring cardio-respiratory signals for broader co-morbidity management," said Jean-Benoît Le Polain de Waroux, professor, Cliniques Universitaires Saint-Luc in Brussels, Belgium, and an investigator in the approval studies for the devices. "The technology is able to adapt the pacing rate to meet the patient's metabolic needs when his or her respiration is increasing, as during exercise."

Each of the devices features the Boston Scientific RightRate technology to adapt the pacing rate to changes in respiration. All three devices include AP Scan, a technology that helps physicians identify and evaluate patients with severe sleep apnea, one of the most prevalent comorbidities in the pacemaker population. The whole family of devices includes radio-frequency (RF) technology, which helps increase the efficiencies of the device implant and periodic in-clinic patient follow-ups. RF technology helps ensure that patients are able to send critical diagnostic health information wirelessly and automatically to their physicians through a monitor at their home.

In addition, Formio includes a full range of features that monitor, track and trend physiological markers related to heart failure, making this device specifically suited to assist in diagnosing patients who are at higher risk of heart failure. These can include those with atrio-ventricular block, a condition in which there is a longer-than-normal delay between the contractions of the heart's chambers. With AP Scan, Respiratory Rate Trend, Heart Rate Variability diagnostics and remote home monitoring via the Latitude NXT system, Formio may help physicians detect changes earlier and make proactive decisions, with the aim of positively impacting clinical outcomes. The new devices also offer an MR-conditional platform, allowing patients to undergo full-body magnetic resonance imaging (MRI) scans.

"We are now able to offer a full portfolio of bradycardia and heart failure devices," said Michael Onuscheck, senior vice president and president of Europe, Middle East and Africa at Boston Scientific. "With our new family of devices, we can provide physicians with diagnostic and therapeutic tools based on a physiological parameter such as respiration."

Inliven, Vitalio and Formio have received the CE mark. Vitalio and Formio are also approved in the United States.

For more information: www.bostonscientific.com

Related Content

Boston Scientific, FDA, IntelliNav XP ablation catheters, Rhythmia Mapping System

Rhythmia Mapping System image courtesy of Boston Scientific

Technology | Ablation Systems| May 23, 2016
Boston Scientific has received U.S. Food and Drug Administration (FDA) approval for two catheters that can be used with...
Watchman, left atrial appendage closure, LAA occluder, LAA. LAAO, laa occluder, left atrial appendage, Watchman

The Boston Scientific Watchman device is currently the only transcatheter LAA occluder cleared for use in the United States.

Feature | Left Atrial Appendage (LAA) Occluders| May 20, 2016 | Dave Fornell
Atrial fibrillation (AF) affects nearly 6 million Americans and the condition puts them at significantly greater risk
News | Atrial Fibrillation| May 19, 2016
Physician-researchers in the College of Medicine at the University of Cincinnati have developed a computerized decision...
Johns Hopkins, virtual heart modeling tool, VARP, arrhythmias, implanted defibrillator

Examples of how the computer model would classify one patient at high risk for heart arrhythmia and another at low risk. Image courtesy of Royc Faddis/Johns Hopkins University.

News | Cardiac Diagnostics| May 17, 2016
May 17, 2016 — An interdisciplinary Johns Hopkins University team has developed a...
News | Ablation Systems| May 11, 2016
Patients with Wolff-Parkinson-White syndrome who receive catheter ablation to cure their abnormal heart rhythms are...
Medtronic, FDA approval, MR-conditional CRT-Ds, defibrillators, Amplia, Compia
Technology | Cardiac Resynchronization Therapy Devices (CRT)| May 11, 2016
Medtronic plc recently announced it received U.S. Food and Drug Administration (FDA) approval for the first and only...
Imricor, Vision-MR ablation catheter, clinical study, MRI guidance
News | Ablation Systems| May 10, 2016
Imricor Medical Systems announced enrollment of the first patients in a clinical study to evaluate the Vision-MR...
Medtronic, Micra transcatheter pacing system, study data, HRS 2016
News | Pacemakers| May 10, 2016
Medtronic plc announced clinical results highlighting the strong safety and performance profile of the miniaturized...
LivaNova, SonR hemodynamic sensor, CRT, heart failure, RESPOND CRT trial, HRS 2016
News | Cardiac Resynchronization Therapy Devices (CRT)| May 10, 2016
The first-ever trial using new SonR hemodynamic sensor technology proves to be safely and effectively applied in...
News | Pacemakers| May 09, 2016
Results from a first-of-its-kind study identify a significant increase in the incidence of atrial fibrillation (AF)...
Overlay Init